Innoscripta Shareholders Approve Dividend and Confirm Supervisory Board with Capital Markets Expertise

The shareholders of innoscripta SE approved a dividend of EUR 4.00 per share for the 2025 financial year at the Annual General Meeting, with all agenda items adopted with a strong majority exceeding 97.6%. This decision reflects shareholder confidence in the company's financial performance and future prospects. The meeting also saw the re-election of three supervisory board members who bring substantial capital markets expertise to their roles.

Philipp von Ilberg, Stefan Berndt-von Bülow, and Dr. Erik Massmann were re-elected to the Supervisory Board, combining extensive experience in capital markets, finance, and international corporate development. Von Ilberg serves as Chairman of the Supervisory Board of CompuGroup SE & Co. KGaA and brings years of experience in complex corporate and capital markets transactions. Berndt-von Bülow has extensive CFO experience in listed technology companies and has successfully led transactions including a NASDAQ IPO. Dr. Massmann most recently served as CFO of the Birkenstock Group and was responsible for its IPO on the NYSE as well as numerous international finance and transformation projects.

With this composition, the Supervisory Board is well positioned to support the company's capital markets strategy and further international growth initiatives. The board's collective experience in guiding companies through public offerings and complex financial transactions provides valuable oversight for innoscripta's strategic direction. This expertise becomes particularly relevant as the company continues to expand its operations and potentially engages with international capital markets.

Shareholders also approved the relocation of the company's registered seat from Munich to Tutzing, a move that has already been implemented. This relocation establishes a clearer organizational structure with key central functions bundled at the new headquarters, while operational units remain in Munich, Cologne, and Frankfurt. The change strengthens the efficiency of the group structure, provides meaningful economic benefits from a fiscal perspective, and creates a solid foundation for further growth, particularly in international markets.

A total of 91.7% of the share capital was represented at the Annual General Meeting, indicating strong shareholder engagement with the company's governance matters. The full voting results are available in the Investors section of the company's website at https://www.innoscripta.com/en/investoren/hauptversammlung-2026. The combination of dividend approval, supervisory board confirmation, and organizational restructuring demonstrates the company's commitment to both shareholder returns and strategic positioning for future growth.